Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Keysight Technologies Inc (KEYS) Price & Performance

Cassava Sciences IncTrade
Keysight Technologies IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Keysight Technologies Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Keysight Technologies Inc trades at $380.3 (market cap $64.93B). The key difference: Keysight Technologies Inc is far larger — about 1648× Cassava Sciences Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Keysight Technologies Inc for 56 Days on average.

FLNAKEYS
Market Cap
$39.40M$64.93B
Volume
759,0181,037,588
Sector
HealthTechnology
52-Week High
$4.64$387.90
52-Week Low
$0.68$159.49
Typical Hold Time
37 Days56 Days
Enterprise Value
-$43.28M$65.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.

The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.

Keysight Technologies Inc

Keysight Technologies (KEYS) trades at $381.49, down 1.65% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $3.07. The stock shows a bullish technical trend, trading near the pivot point of $380 with support at $377. Revenue for 2025 reached $5.38B, with net income of $850M, and the company is actively advancing in AI infrastructure and 6G testing, as highlighted in recent product launches and collaborations.

Outlook remains positive with a consensus price target of $416.63, representing a 9.2% upside, supported by accelerating earnings and strong AI demand. Risks include high valuation multiples, such as a P/E of 51.61, and supply constraints that may limit near-term revenue conversion despite surging orders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
73% Buy27% Sell
Avg holding period · 37 Days
KEYS
100% Buy0% Sell
Avg holding period · 56 Days

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Keysight Technologies Inc

Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.

Read more on KEYS →